RxDoctor Payments Data

Corey Lejeune, DPM

Foot & Ankle Surgery · Fullerton, CANPI 1891949426

Payments from drug & device makers

$3,173in general payments, 2019–2025

Across 67 payments — averaging $47.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Treace Medical Concepts, Inc.$1K
  • Biotissue Holdings Inc.$642
  • Organogenesis Inc.$455
  • Stryker$290
  • Abbott$127
  • Osiris Therapeutics Inc.$124
  • plus $479 from 11 others

What the payments were for

  • Travel & lodging$72923%
  • Food & beverage$2,44477%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,173 in reported general payments places this provider in the 60th percentile of 1,126 foot & ankle surgery providers in California.

See all foot & ankle surgery providers in California

Medicare billing

Part B allowed, 2024
$835,035
Medicare patients
382
Services billed
5,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.12$4,244
Econazole Nitrate76$3,865
Ciclopirox177$2,621
Clotrimazole25$995
Ketoconazole39$927
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip37$479
Terbinafine Hcl47$465
Gabapentin72$390
Cephalexin33$194
Naproxen35$188
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$130
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim11$63
Meloxicam11$28

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$87$4,24412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,126 foot & ankle surgery providers in California.

Other foot & ankle surgery in Fullerton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →